Skip to main content

Opioid Abuse

3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Acura Pharmaceuticals
2 programs
2
40/0mg taken firstPhase 2
Acurox 5/30mg taken firstPhase 21 trial
Active Trials
NCT00699010Completed30Est. Aug 2008
Pfizer
PfizerNEW YORK, NY
1 program
1
40/0mg taken firstPhase 21 trial
Active Trials
NCT01030406Completed49Est. Feb 2010
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening ToolN/A1 trial
Active Trials
NCT03936985Completed1,464Est. May 2023
MediciNova
MediciNovaLA JOLLA, CA
1 program
MN-166PHASE_21 trial
Active Trials
NCT01740414Completed28Est. May 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MediciNovaMN-166
Pfizer40/0mg taken first
Acura PharmaceuticalsAcurox 5/30mg taken first
Purdue PharmaValidation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool

Clinical Trials (4)

Total enrollment: 1,571 patients across 4 trials

NCT01740414MediciNovaMN-166

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

Start: Nov 2012Est. completion: May 201728 patients
Phase 2Completed
NCT01030406Pfizer40/0mg taken first

Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users

Start: Jan 2010Est. completion: Feb 201049 patients
Phase 2Completed
NCT00699010Acura PharmaceuticalsAcurox 5/30mg taken first

Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse

Start: Mar 2008Est. completion: Aug 200830 patients
Phase 2Completed
NCT03936985Purdue PharmaValidation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool

Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool

Start: Nov 2019Est. completion: May 20231,464 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.